Izel F Sørensen1, Ana I Vazquez, Marguerite R Irvin, Peter Sørensen, Barry R Davis, Charles E Ford, Eric Boerwinkle, John H Eckfeldt, Donna K Arnett. 1. Departments of aBiostatistics bEpidemiology, University of Alabama at Birmingham, Birmingham, Alabama cDepartment of Biostatistics dDepartment of Epidemiology, Human Genetics & Environmental Sciences, The University of Texas Health Science Center at Houston, Houston, Texas eDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA fDepartment of Molecular Biology and Genetics, Center for Quantitative Genetics and Genomics, Aarhus University, Denmark.
Abstract
OBJECTIVE: The aim of this study was to investigate whether there is a genotype-by-treatment interaction in patients experiencing stroke and treated with one of three antihypertensive drugs, that is chlorthalidone, amlodipine, or lisinopril. PARTICIPANTS AND METHODS: A population of 436 African Americans and 539 whites who had experienced stroke in the GenHAT study were genotyped for 768 single nucleotide polymorphisms (SNPs) in 280 candidate genes. To detect a genotype-by-treatment interaction, we used the Pearson's χ-test to assess whether the genotype frequencies differed at the single SNP level for the three drug treatment groups. From these single SNP analyses, we derived a summary statistic for the degree of association at the gene and gene complex levels. This was done by grouping SNPs using information on gene locations and defining gene complexes on the basis of protein-protein interactions. To assess the statistical significance of the observed test statistic, we derived an empirical P-value by simulating data under the null hypothesis. RESULTS: We found that, in patients who have experienced stroke, there is a significant genetic difference between hypertension drug treatment groups. In African Americans, SNP rs12143842 showed a significant association (P<0.001) with drug treatment. At the gene level, HNRNPA1P4 and NOS1AP in African Americans and PRICKLE1 and NINJ2 in non-Hispanic whites were significantly associated (P<0.01) with drug treatment, whereas none of the gene complexes tested showed significance. CONCLUSION: On the basis of the genetic differences between drug treatment groups, we conclude that there may be an interaction between certain genotypes and antihypertensive treatment in stroke patients. This needs to be replicated in other studies.
OBJECTIVE: The aim of this study was to investigate whether there is a genotype-by-treatment interaction in patients experiencing stroke and treated with one of three antihypertensive drugs, that is chlorthalidone, amlodipine, or lisinopril. PARTICIPANTS AND METHODS: A population of 436 African Americans and 539 whites who had experienced stroke in the GenHAT study were genotyped for 768 single nucleotide polymorphisms (SNPs) in 280 candidate genes. To detect a genotype-by-treatment interaction, we used the Pearson's χ-test to assess whether the genotype frequencies differed at the single SNP level for the three drug treatment groups. From these single SNP analyses, we derived a summary statistic for the degree of association at the gene and gene complex levels. This was done by grouping SNPs using information on gene locations and defining gene complexes on the basis of protein-protein interactions. To assess the statistical significance of the observed test statistic, we derived an empirical P-value by simulating data under the null hypothesis. RESULTS: We found that, in patients who have experienced stroke, there is a significant genetic difference between hypertension drug treatment groups. In African Americans, SNP rs12143842 showed a significant association (P<0.001) with drug treatment. At the gene level, HNRNPA1P4 and NOS1AP in African Americans and PRICKLE1 and NINJ2 in non-Hispanic whites were significantly associated (P<0.01) with drug treatment, whereas none of the gene complexes tested showed significance. CONCLUSION: On the basis of the genetic differences between drug treatment groups, we conclude that there may be an interaction between certain genotypes and antihypertensive treatment in strokepatients. This needs to be replicated in other studies.
Authors: Nicholas L Smith; Janine F Felix; Alanna C Morrison; Serkalem Demissie; Nicole L Glazer; Laura R Loehr; L Adrienne Cupples; Abbas Dehghan; Thomas Lumley; Wayne D Rosamond; Wolfgang Lieb; Fernando Rivadeneira; Joshua C Bis; Aaron R Folsom; Emelia Benjamin; Yurii S Aulchenko; Talin Haritunians; David Couper; Joanne Murabito; Ying A Wang; Bruno H Stricker; John S Gottdiener; Patricia P Chang; Thomas J Wang; Kenneth M Rice; Albert Hofman; Susan R Heckbert; Ervin R Fox; Christopher J O'Donnell; Andre G Uitterlinden; Jerome I Rotter; James T Willerson; Daniel Levy; Cornelia M van Duijn; Bruce M Psaty; Jacqueline C M Witteman; Eric Boerwinkle; Ramachandran S Vasan Journal: Circ Cardiovasc Genet Date: 2010-05-05
Authors: Elsayed Z Soliman; George Howard; Mary Cushman; Brett Kissela; Dawn Kleindorfer; Anh Le; Suzanne Judd; Leslie A McClure; Virginia J Howard Journal: J Am Coll Cardiol Date: 2012-04-17 Impact factor: 24.094
Authors: Olli T Raitakari; Jaana Blom-Nyholm; Tuomas A Koskinen; Mika Kähönen; Jorma S A Viikari; Terho Lehtimäki Journal: Ann Med Date: 2009 Impact factor: 4.709
Authors: Katharina Wolf-Maier; Richard S Cooper; José R Banegas; Simona Giampaoli; Hans-Werner Hense; Michel Joffres; Mika Kastarinen; Neil Poulter; Paola Primatesta; Fernando Rodríguez-Artalejo; Birgitta Stegmayr; Michael Thamm; Jaakko Tuomilehto; Diego Vanuzzo; Fenicia Vescio Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Alexander G Bassuk; Robyn H Wallace; Aimee Buhr; Andrew R Buller; Zaid Afawi; Masahito Shimojo; Shingo Miyata; Shan Chen; Pedro Gonzalez-Alegre; Hilary L Griesbach; Shu Wu; Marcus Nashelsky; Eszter K Vladar; Dragana Antic; Polly J Ferguson; Sebahattin Cirak; Thomas Voit; Matthew P Scott; Jeffrey D Axelrod; Christina Gurnett; Azhar S Daoud; Sara Kivity; Miriam Y Neufeld; Aziz Mazarib; Rachel Straussberg; Simri Walid; Amos D Korczyn; Diane C Slusarski; Samuel F Berkovic; Hatem I El-Shanti Journal: Am J Hum Genet Date: 2008-10-30 Impact factor: 11.025
Authors: R O Akinyemi; B Ovbiagele; A Akpalu; C Jenkins; K Sagoe; L Owolabi; F Sarfo; R Obiako; M Gebreziabher; E Melikam; S Warth; O Arulogun; D Lackland; A Ogunniyi; H Tiwari; R N Kalaria; D Arnett; M O Owolabi Journal: Cardiovasc J Afr Date: 2015 Mar-Apr Impact factor: 1.167